| Literature DB >> 32461929 |
Moslem Bahadori1, Seyed Mahdi Rezayat Sorkhabadi2, Soheila Fazli Tabaei3, Dariush D Farhud1,4.
Abstract
Recently convergence science was proposed and promoted in a large report from US National Science Foundation and Department of Commerce (NSF/DOC). The report was entitled "converging technologies for improving human performance. "It was dealing with converging of four technologies as: Nanotechnology, Biotechnology, Information technology and Cognitive science (NBIC). The report has gained tremendous popularity throughout the academia and scientific world. On Dec 2015 in a monthly meeting of the department of basic science of Iran Academy of Medical Science, the report of NSF/DOC on NBIC has been discussed. A working group has been established for more discussion and application in Iran. Several seminars in this regard have been performed, and presently this technology has been started as pilot in some technical universities in Iran. After US National Research Council (NCR) in the year 2014 and Massachusetts Institute of Technology (MIT) on convergence in biomedicine, the concept opened a new gate to approach solving medical and health care problems; the convergence technology in biomedical sciences has become interested and gained great popularity among the working group of convergence science in academy of medical science. This technology can lead to advances in fighting chronic diseases such as cancer, dementia, psychiatric disorders, disease of aging and others. The following is summary of proposed discussions in several gathered groups of scientists in this field. Copyright© Iranian Public Health Association & Tehran University of Medical Sciences.Entities:
Keywords: Aging; Biomedicine; Cancer; Chronic disease; Convergence; Interdisciplinary approach
Year: 2020 PMID: 32461929 PMCID: PMC7231700
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Convergence medicine-focused fields
| Translational medicine | There have been calls for many years to improve and better engage the medical and research workforces in translational medicine. This recognizes the importance of bench to bedside translation, and also bedside to broader health system uptake of clinical practices, guideline development. We see translational medicine and convergence medicine as two concepts which must be complementary to achieve best outcomes in translating innovations. The working steps of translational medicine, as outlined by Licinio include: (T0) discovery (via pre-clinical, clinical and epidemiological science), (T1) bench to bedside, (T2) bedside to clinical applications (clinical trials), (T3) translation to policy and health care guidelines, (T4) assessment of health policy and usage, and (T5) global health applications. All areas of medical research contribute to this area, including molecular biology, genetics, pharmacology, imaging, epidemiology and immunology. Key example. An early and robust example of translational medicine comes from smallpox. Sir Edward Jenner made a clinical observation that dairymaids who contacted cowpox appeared to be protected from smallpox. He hypothesized, then demonstrated, that vaccination with serum from recovered dairymaids would protect against smallpox. Model vaccines were developed for smallpox which led to a coordinated global health campaign leading to its eventual eradication in 1980. |
| Geroscience | The field of exploration of the mechanisms of ageing has been termed geroscience, an interdisciplinary field that aims to understand the relationship between age-related diseases. In this field, researchers in a variety of disciplines may work together, sharing data and ideas, with a common goal of explaining and intervening in age-related diseases. ‘Compression of morbidity’ is a major focus of geroscience research. ‘Compression of morbidity’ is a concept whereby scientists discover ways to decrease the period of an individual’s life during which they are suffering poor health. With this aim, researchers hope to postpone and reduce disease onset, disability, dependency and suffering. The exact mechanisms of aging are still under debate, however there are a number of mechanisms which are generally agreed upon (see for discussion). Geroscience is supported by the Trans-National Institutes of Health (NIH) GeroScience Interest Group with some 20 NIH institutes and centers participating, the group was founded by program scientists from National Institute of Aging and other institutes to find ways to collaborate and coordinate. Key example. The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. Rapamycin is an inhibitor of Mammalian target of rapamycin (mTOR), a kinase at a key signaling node that integrates information regarding extracellular growth factor stimulation, nutrient availability and energy supplies. In rodent studies, the aging traits found to be ameliorated by rapamycin were either related to immune system changes (e.g. plasma immunoglobulin concentrations, frequency of specific T cell subsets, cytokine concentrations in blood and heart, response to vaccination), age-related alterations in body mass, organ size and dimensions (body weight, fat mass, lean mass, thyroid follicle size, cardiac dimension, heart weight), tumors and pre-cancerous lesions, as well as neurobehavioral changes (motor activity, learning and memory). Translational studies that assess rapamycin’s effects on human aging and age-related disease are within reach and have actually been initiated at some sites. |
| 3D printing | Background and overview. Medical applications for 3D printing are expanding rapidly and are expected to dramatically change health care. Medical uses for 3D printing, both actual and potential, can be organized into several broad categories according to Ventola et al, including: tissue fabrication; creation of customized prosthetics, implants, and anatomical models. The application of 3D printing in medicine can provide many benefits, including: the personalization of medical products, drugs, and equipment; lowering cost; increased productivity for staff; the democratization of design and manufacturing; and enhanced collaboration. |
| Behavioral neuroeconomics | This field aims to provide a neural foundation for economics models of health-related choices and decision making. It involves problems at the intersection of psychology, neuroscience and economics. Key example. A recent study explored the relationship between adolescent preference for immediate reward and neural activation in brain regions mediating impulsive/habitual behavioral choices as well as reflective/executive behavioral choices. This was a model of understanding adolescent substance use. Results support relations between competing executive and reward valuation neural networks and temporal decision making. This is now a biomarker for treatment and prevention of substance use. |
Convergence medicine-focused research organizations
| Frances Crick Institute | Overview and strategic aims. A translational research centre opening in 2015, its strategic aims are to pursue discovery without boundaries; create future science leaders; collaborate widely in the UK; accelerate translation; engage and inspire the public. It has developed is a consortium of six UK-based scientific and academic organizations—the Medical Research Council (MRC), Cancer Research UK (CRUK), the Wellcome Trust, UCL (University College London), Imperial College London and King’s College London. It is anticipated that it will employ approximately 1250 scientists. Processes for promoting convergence:
The internal structure is not arranged along disciplinary lines. Instead, the bottom-up development of ‘interest groups’ that bring together researchers from across the organization to share insights and plan activities in areas of common scientific interest is encouraged. Building constructed to encourage mixing among all scientific staff i.e. break out spaces, transparent partitions, open spaces. Hiring will focus on drawing talent from physical sciences, engineering and clinical sciences. Providing PhD opportunities to individuals from an expressed diverse array of backgrounds (non-clinical, clinical, physical sciences, undergraduate and masters level). Providing PhD students with industry experience to maximal commercial career opportunities. Expressing interest in collaboration between organizations via a mix of secondments, long-term joint appointments, ‘satellite groups’ (a mechanism to enable university-based research groups to establish a small outpost at the Crick). |
| Singularity University | Overview and strategic aims. A Silicon Valley-based, not-for-profit educational institution. To provide educational programs, partnerships and a startup accelerator to help individuals, businesses, institutions, investors, non-governmental organizations and governments to understand and utilize innovative technologies, primarily computing-based technologies. Processes for promoting convergence:
Coordination of Exponential Medicine, a conference for individuals ‘who want to break across traditional silos, cross-fertilize, understand and leverage rapidly developing technologies to innovate in health care’. This conference covers innovations such as 3D printing, stem cell therapies, artificial intelligence, lab-on-a-chip diagnostics, low-cost genomics, large-scale bioinformatics and synthetic biology. Graduate Studies Program: a 10 week immersive learning program to educate future leaders in computing-based innovations. Executive program: a weeklong workshop for corporate executives to learn tools to predict and evaluate how emerging technologies will disrupt and transform their industries and companies. Successes. 8689 people educated through the above programs. 93 countries represented through education. 109 impact initiatives developed. |
| Michelson Center for Convergent Bioscience, University of Southern California | Overview and strategic aims. A major institution which aims to provide a workspace to allow collaboration between physicians, engineers and scientists to fast track the invention of new biomedical devices and development of precision medicine. It houses researchers from the USC Dornsife College of Letters, Arts, and Sciences, the USC Viterbi School of Engineering and the Keck School of Medicine. Processes for promoting convergence:
Will house 20 to 30 principal investigators with laboratories employing hundreds of researchers and students. 190 000-square-foot center. Flexible laboratories. Recruitment of staff from a variety of scientific backgrounds. Successes. |
| University of California, San Francisco | Overview and strategic aims. UCSF is dedicated solely to graduate education and research in health and biomedical sciences, as well as health service provision through medical centers. UCSF is uniquely positioned to promote convergence science as it has a large number of transdisciplinary institutes. Processes for promoting convergence. There are a number of transdisciplinary institutes within UCSF promoting convergence science and the imbedding of convergence science into clinical care. These include:
Center for Digital Health Innovation— serves to develop digital health innovations. Has successfully developed multiple new digital health products. Center for Computational Health Sciences—serves to develop machine learning and deep learning analytic abilities in medicine. Center for Transdisciplinary ELSI Research in Translational Genomics—serves as a novel resource for ethical, legal, social and policy analysis of emerging issues in translational genomics. |
Potential benefits of enhanced convergence medicine opportunities
| Medical doctors | Professional development | Greater job satisfaction due to creativity and novel learning; new challenges; diversified skill-set. Greater appreciation and understanding for clinical, research and commercialization procedures. |
| Non-medical researchers and innovators | Professional development | Greater job satisfaction due to creativity and novel learning; enhanced access to clinical care processes and procedures; greater appreciation for the clinical care environment; greater exposure to commercialization processes and opportunities. |
| Enhanced clinical practice | Diversified and up-skilled workforce; greater workforce satisfaction; improved clinical innovations and hence patient outcomes. | |
| Employing health service | Mutually beneficial partnerships | Partnering with other public and private organizations; potential for economic development from commercial successes. |
| Recruitment and retention | Enhanced workforce retention | |
| Research institutions | Improved novelty of research | Increases in transdisciplinary research work. Increased opportunities for commercialization. |
| Private enterprises | Improved access to translational research innovations | Increased engagement of clinicians and researchers in commercialization pursuits. Increased economic opportunities. |
| Community | Improved standards of health care | Greater innovation from researchers, clinicians and private enterprises. |